£1.54m grant backs automated radiopharmaceutical manufacturing project
Medicines Discovery Catapult and Astral Systems have secured £1.54m from Innovate UK to develop automated laboratory processes for radiopharmaceutical manufacturing.
The project aims to connect currently fragmented production and laboratory processes through an integrated digital workflow, improving data recording, process consistency and manufacturing efficiency.
The funding was awarded through Innovate UK’s Labs of the Future competition, part of the Transforming Medicines Manufacturing Innovation programme.
Radiopharmaceuticals contain radioactive isotopes, known as radionuclides, which decay over time. This creates particular manufacturing challenges because medicines must be produced and delivered quickly to maintain their potency.
More than 700,000 NHS procedures rely on radiopharmaceuticals each year, according to Medicines Discovery Catapult (MDC), with demand expected to increase as new targeted therapies progress towards clinical use.
Digital automation for radiopharmaceutical production
Currently, laboratory stages involved in radiopharmaceutical production can rely on separate systems, manual record-keeping and handovers between processes. These disconnected workflows can increase the risk of errors and create delays, potentially affecting the efficiency and reliability of manufacturing.
The project will combine MDC’s expertise in radiopharmaceutical development with Astral Systems’ engineering capabilities to create a connected and automated laboratory workflow.
The system will integrate data recording and transfer between production stages, with the aim of reducing manual processes and improving reproducibility.
It will also incorporate virtual digital avatars: computer models that allow researchers to simulate, test and optimise laboratory processes before carrying out physical experiments.
Dr Mike Strange, chief executive officer of Medicines Discovery Catapult, said: “The UK has world-class science in radiopharmaceuticals, but it needs the development and manufacturing capability to match if we are to realise the economic and health benefits of this fast-growing field.”
He added: “This project is an important step towards ensuring the digital infrastructure is in place to support the next generation of radiopharmaceutical development in the UK and help bring new treatments closer to patients.”
Copper isotopes to demonstrate the technology
The partners will use copper-64 and copper-67 as pilot radionuclides to develop and demonstrate the integrated manufacturing approach.
The two isotopes are being investigated for complementary applications in diagnostic imaging and targeted radiopharmaceutical therapy. Copper-64 can be used for imaging, while copper-67 has potential applications in targeted radionuclide treatment.
The project aims to establish processes that can subsequently be adapted for other radionuclides and transferred between laboratories.
Talmon Firestone, chief executive officer of Astral Systems, said: “Isotopes decay constantly, so every step between the lab and the patient matters.”
He added: “This project brings those steps together into one automated, digital workflow, giving researchers more reliable data and the UK a firmer base for the treatments that follow.”
Supporting UK medicines manufacturing
The project forms part of wider efforts to modernise medicines manufacturing through digitalisation, automation and advanced laboratory technologies.
Dr Hareklea Markides, innovation lead for medicines manufacturing at Innovate UK, said: “This project demonstrates the UK’s strength in medicines manufacturing innovation and highlights the value of our investment through the Labs of the Future programme.”
She added: “With demand for radiopharmaceuticals continuing to grow, a digital-first production process has the potential to improve resilience, increase access and ultimately benefit patients.”
By developing a connected approach to radiopharmaceutical production, MDC and Astral Systems aim to improve the consistency and scalability of laboratory processes and support the translation of new radioactive medicines into clinical supply.




